“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra
From Washington, DC
- Govexec points out,
- “A lame-duck Congress is suddenly hastening the process to find a new long-term leader of a governmentwide watchdog agency that has drawn the ire of the Trump administration.
- “House and Senate Republicans faced calls over the past two years to start the bipartisan process of interviewing candidates to lead the Government Accountability Office.
- “Under the current process, the selection of the GAO comptroller general begins with a commission of 10 senior House and Senate lawmakers from both parties that recommends individuals for the position to the president.
- “Whoever the president selects is subject to Senate confirmation for one nonrenewable 15-year term. The last time lawmakers vetted candidates for GAO’s top job in 2010, the congressional commission spent more than a year on its search.
- “This time around, members of the commission are being given a single day to come up with candidate recommendations, after receiving notice on Veterans Day. The commission is meant to recommend at least three candidates for the job.” * * *
- “The Washington Sun reported last month that the Trump administration is floating the idea of having Office of Management and Budget Deputy Director Eric Ueland serve as the next GAO comptroller general. The HSGAC aide said the committee is aware that Ueland’s name has been floated for the job.
- “Ueland said Monday at an industry conference that the Trump administration’s reshaping of the federal government has been “long overdue.” * * *
- “The Senate in May 2025 voted 52-45 along party lines to confirm Ueland as OMB’s second-in-command. A potential vote to confirm him as GAO comptroller could come down to a few outgoing Republican senators who have challenged some of the Trump administration’s decisionmaking.
- “The comptroller general position opened up in December 2025 when Gene Dodaro retired. Orice Williams Brown, the agency’s chief operating officer, is currently leading GAO in an acting capacity.”
- Beckers Health IT reports,
- “CMS is extending its nationwide freeze on new Medicare enrollments for hospice and home health agencies for an additional six months as part of its efforts to combat fraud, waste and abuse.
- “The agency announced the initial six-month moratorium May 13 and said in a Nov. 12 news release that the conditions prompting the restrictions have not sufficiently improved to lift them.
- “The extension will continue to prohibit new Medicare enrollment applications and certain changes in majority ownership for hospice and home health providers nationwide.
- “However, CMS is modifying the restrictions to allow currently enrolled hospices and home health agencies to add new practice locations under their existing Medicare enrollments. The original moratorium prohibited these additions.
- ‘The extension will not affect existing Medicare enrollments or prevent currently enrolled providers from continuing to deliver services.”
- Beckers Behavioral Health relates,
- “Mark Cuban Cost Plus Drug Co. will lead research teams laying the groundwork for a domestically manufactured ibogaine product, part of an HHS effort to develop the psychedelic as a potential treatment for post-traumatic stress disorder and other serious mental illnesses, including among veterans.
- “HHS committed up to $4.9 million to the effort through the Advanced Research Projects Agency for Health, the department announced Nov. 12. The Cost Plus-led teams will build the regulatory, clinical, chemical and engineering foundation for a single-molecule ibogaine hydrochloride product. Separately, Beond will generate clinical data on the drug’s safety, dosing, efficacy and durability. All awardees will make their research data open source.
- “HHS Secretary Robert F. Kennedy Jr. unveiled the awards alongside Department of Veterans Affairs leaders the day after Veterans Day. The funding will support investigational new drug applications for future U.S. clinical trials, secure clinical-grade ibogaine and build domestic manufacturing processes.”
- The American Hospital Association News tells us,
- “The AHA Nov. 12 published a new issue brief, Advancing Health Literacy in Hospitals and Health Systems, that examines gaps within health literacy and highlights examples of organizational strategies used by hospitals. This resource is designed to help hospital leaders, clinical staff and community health partners build a comprehensive, system-level approach to improving health literacy. LEARN MORE”
From the U.S. Office of Personnel Management front,
- Federal News Network interviews OPM’s Associate Director for Health Caren and Insurance Matt Kiley about the ongoing Federal Benefits Open Season. Check it out.
- Govexec discusses
- “What retirees should know about health insurance during Open Season
- “Federal retirement benefits expert Tammy Flanagan and Executive Editor Tanya Ballard Brown discuss what federal employees nearing retirement and current retirees should consider when choosing health coverage during Open Season.”
- “What retirees should know about health insurance during Open Season
- Per an OPM Federal Register notice,
- OPM is extending the current suspension of applications for coverage in FLTCIP in light of ongoing volatility in long term care costs and a greatly diminished insurance market. The original suspension notice was published at 87 FR 69345 (November 18, 2022) and suspended FLTCIP applications for 24 months, as authorized by 5 CFR 875.110. The suspension was extended through a second notice for an additional 24 months, published at 89 FR 89662 (November 13, 2024).
- This extension, which will take effect on December 19, 2026, complies with the requirements of § 875.110(d), which requires OPM to issue a Federal Register notice at least 30 days before the end of the suspension period in order to effectuate another suspension not to exceed 24 additional months. As with the current suspension period, no applications for FLTCIP coverage will be accepted during the extension period, and current enrollees may not apply to increase their coverage. The enrollment status or benefit eligibility of current enrollees will not change due to the suspension. For those in a claim status, there is no change to coverage and the claims reimbursement process.
From the U.S. Food and Drug Administration front,
- Cardiovascular Business reports
- “California-based Tandem Diabetes Care is recalling more than 80,000 insulin pumps due to a risk of false-positive occlusion alarms. The recall includes several models of the company’s Tandem Mobi Insulin Pumps, which are battery-operated devices that provide both long-acting and short-acting bolus insulin doses.
- “Unlike many recalls, these devices can still be used for patient care. Tandem Diabetes care has provided specific recommendations patients should follow going forward to avoid any risk.”
- Beckers Hospital Review relates,
- “The FDA has shelved the Commissioner’s National Priority Voucher program, which former Commissioner Marty Makary launched in 2025 to cut drug review times to one to two months, according to a Nov. 12 Reuters report citing six sources and internal documents. HHS disputes that characterization, saying the pilot is ongoing.
- “No new drugs have received a voucher since Dr. Makary left the agency in May, and an executive council of political appointees that oversaw the reviews has gone dormant, Reuters reported. Of the 22 drugs given a voucher, a dozen have been approved, including five since Dr. Makary’s departure. For several drugs, the program sped approval by eight months or more, according to the report.
- “One source told Reuters that FDA leadership told companies the agency is not moving forward with the program but is keeping applications open, and that applications submitted now do not advance. For the nine drugs still in the program, career scientists have resumed overseeing review timelines, two sources said.
- “HHS spokesperson Emily Hilliard said the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing to refine the framework, according to Reuters. The agency did not respond to questions about the departure of the program’s lead or whether a new coordinator has been named.”
No Surprises Act News
- Beckers Payer Issues reports,
- “Researchers at the USC Schaeffer Institute argued Nov. 6 that Congress should preserve the NSA’s consumer protections while making targeted fixes to arbitration rather than scrapping it, as the Pallone bill and the Paragon proposal would each do in different ways. The piece recommended letting arbitrators pick any value within the range of the two offers instead of the current baseball-style format, scaling arbitration fees to the value of disputes, and strengthening eligibility screening so arbitrators have no financial incentive to let ineligible claims proceed.”
- Fierce Healthcare adds,
- “The No Surprises Act’s independent dispute resolution process cost employer plans $8.39 billion in 2025, according to a new analysis.
- “Researchers at the Employee Benefit Research Institute combed federal IDR data and found that these additional costs equal about 63 cents per $100 spent by employer-based insurance plans. The total includes $4.73 billion in costs incurred in the first half of the year as well as $3.66 billion in the second half of 2025.
- “Even when EBRI analysts used different thresholds to exclude outlier awards, such as a costs that were unusually high, they still landed on an estimate of at least $8.02 billion, per the study.
- “The researchers note that this data doesn’t necessarily paint the full picture, as it only encompasses cases that proceeded to IDR. The study doesn’t include information on claims that were settled outside of arbitration, administrative costs, any changes in networks or provider rates or the cost associated with patient protections.”
From the public health and medical / Rx research front,
- Beckers Clinical Leadership reports,
- “The share of U.S. deaths attributed to flu in the last week of October was higher than in any comparable week of the past decade, according to preliminary CDC data.
- “In the week ending Oct. 31, 0.3% of all deaths were due to flu, according to the agency’s latest FluView report. That share held stable from the week before but has trended upward over the past seven weeks. It is nearly double the next-highest weekly figure of the past 10 seasons (0.16% in 2022-23) and well above the 0.02% to 0.08% recorded in most other recent seasons.
- “The early climb tracks with broader flu activity, which the CDC said is higher than typically seen this time of year. Still, the agency cautioned that an earlier rise does not necessarily mean a higher peak or a more severe season, and its preliminary assessment rates the season’s severity as low across all age groups so far.
- “Early-season deaths also typically make up a small share of total seasonal mortality, as flu deaths generally climb through January and February.
- “The CDC estimates at least 1,400 flu deaths nationwide so far this season, along with 1.7 million illnesses and 25,000 hospitalizations. Three pediatric flu deaths have been reported for the 2026-27 season.”
- Healio relates,
- “MMR vaccination normally occurs at ages 12 to 15 months and 4 to 6 years.
- “Pediatricians can recommend an earlier dose based on other risk factors, such as a nearby outbreak.” * * *
- “Adam Ratner, MD, MPH, FAAP, a member of the American Academy of Pediatrics’ Committee on Infectious Diseases, said there are many states with overall vaccination rates of 93% to 94% but school districts with rates that are many percentage points lower.
- “That is meaningful because if you get someone who travels, gets measles and comes back and gives it to someone in that community, then that becomes a place where a measles outbreak can happen,” Ratner told Healio.
- “This is an example of a scenario in which pediatricians and parents might discuss an early dose of MMR vaccine for an infant, based on the CDC recommendation that it can be given between 6 and 11 months in situations where there is ongoing spread of measles in the community.”
- The Wall Street Journal tells us,
- “The American Cancer Society recommended that middle-aged men get screened regularly for prostate cancer.
- “The new guidelines recommend that men aged 50 to 69 receive a prostate-specific antigen blood test every two years.
- “Men at high risk, including Black men, should receive an annual PSA-based screening starting at age 45.” * * *
- “For years, the nation’s largest cancer-fighting organization advised men to decide with their doctors whether to test for prostate cancer. Widespread testing in the late 1980s and 1990s led to overtreatment and damaging side effects for many men, raising questions about the benefits of testing.
- “The cancer society changed its guidance because there is now more evidence that PSA-based screening saves lives and there are better tools to prevent treating the wrong patients, said Robert Smith, director of the cancer society’s Center for Early Cancer Detection and senior author of the guidelines. The hope is also to stem the increase in diagnoses of late-stage prostate cancer. He pointed to data from a more than two-decade-long study in Europe that found 13% fewer deaths among men ages 55 to 69 who received regular PSA tests.”
- Cardiovascular Business informs us,
- “Semaglutide is sold by Novo Nordisk under the brand names Wegovy and Ozempic, and dulaglutide is sold by Eli Lilly and Company under the brand name Trulicity. Tirzepatide, meanwhile, is a popular dual GIP and GLP-1 hormone receptor agonist sold by Eli Lilly and Company under the brand names Mounjaro and Zepbound.
- “What stood out across the class was that subcutaneous semaglutide was the only agent associated with a significant reduction in AFib, while tirzepatide—which usually outperforms it on weight and glucose—ranked lower, and dulaglutide was linked to more AFib,” co-authors Lucas M. Barbosa and Vinícius Martins Rodrigues Oliveira, MD, told Cardiovascular Business. Barbosa is with the Federal University of Minas Gerais in Brazil, and Oliveira is with the Federal University of Goiás in Brazil.” * * *
- “Click here to read the full study.”
- The New York Times lets us know,
- “It’s not every day that a 76-year-old woman is asked to talk nonsense — repeating “ga ba da” and “ka pa ta” as fast as she can.
- “All with sensors affixed to her tongue, forehead, chin, jaw, upper and lower lip recording her tiniest muscle movements in the name of science.
- “The goal is to analyze changes in people’s speech to try to predict their likelihood of developing dementia and track shifts in their brain health.
- “We are seeing differences that humans can’t see or can’t really detect by their ears, but it’s there years and years before cognitive decline,” said Marziye Eshghi, the researcher leading the effort at Mass General Brigham University of Health Professions in Boston.
- “Dr. Eshghi’s project measures about 130 different speech-related features in participants like the 76-year-old woman from suburban Boston, who asked to be identified by her first name, Deb, to protect her privacy. The data is run through artificial intelligence algorithms and compared with known biological risk factors for Alzheimer’s. In preliminary results, speech-related data was better than cognitive testing at identifying Alzheimer’s risk in cognitively unimpaired older people, Dr. Eshghi’s team reported.”
- Health Day adds,
- “Nearly half of U.S. adults say they’re more anxious this year than last, a recent poll finds
- “Regular exercise, even short walks that add up over the day, may help ease anxiety and depression
- “Sleep, nature, healthy eating and less social media scrolling can also lift mood, experts say.”
- Per STAT News,
- “A massive scientific collaboration meant to unravel the mysteries of the human brain has produced the most detailed map yet of the basal ganglia, a region closely associated with a wide array of psychiatric and neurologic disorders.
- “Researchers profiled more than 25 million cells, generating a deluge of data that allowed them to generate a “parts list” of what cells are present in the basal ganglia and how they’re arranged. In the process scientists discovered a new type of neuron that appears to play a role in schizophrenia. They also identified cell types linked to depression, bipolar disorder, and post-traumatic stress disorder.
- “Demonstrating the value of the work, the scientists produced preliminary evidence that they can use their more detailed understanding of brain cell types to deliver therapies with increased precision. Authors working in mouse models of Parkinson’s disease showed that a gene therapy designed to work in a subset of basal ganglia cells was as effective as a blanket approach; it was also safer.
- “These and other related findings were published across more than two dozen studies on Thursday in a special issue of the journal Cell. The cellular map is the outcome of hundreds of scientists working in concert across nine countries and more than 50 institutions. Researchers liken the scale and ambition of this work to the Human Genome Project, and one of their goals is to generate a map of the whole brain, which contains around 100 billion neurons and just as many other cells that play supportive roles.”
From the U.S. healthcare business and artificial intelligence front,
- The Wall Street Journal reports,
- “Germany’s Merck MRK KGaA raised its annual guidance for the third time this year after reporting top-line growth across its three businesses.
- “The Darmstadt, Germany-based conglomerate has moved to reshuffle its portfolio, which spans life-science tools and services, pharmaceuticals and chemicals, since Kai Beckmann became its chief executive officer earlier this year, when Belen Garijo left for Sanofi.
- “The company said Thursday that its latest guidance increase—which follows earlier upgrades alongside its earnings for the first and second quarters—reflected improvements in its underlying performance as well as favorable currency movements, and attributed its third-quarter results to the strength of its integrated business model.”
- Beckers Hospital Review relates,
- “Duluth, Minn.-based Essentia Health’s credit rating was upgraded to “A” from “A-” by Fitch.
- “The upgrade reflects the system’s leading market position across its three-state service area and improved financial flexibility, Fitch said in a Nov. 11 report.
- “The credit agency said it expects Essentia’s operating EBITDA margins to improve moderately over the medium term, driven by retail and specialty pharmacy growth, improved length of stay and throughput, workforce efficiency and expanded access. Fitch added that a manageable capital plan and easing leverage should continue to strengthen the system’s balance sheet.
- “On Sept. 29, Essentia and Bloomington, Minn.-based HealthPartners announced plans to combine to form a 22-hospital nonprofit health system with more than 135 clinics and 6,000 clinicians. The combined organization will operate as HealthPartners and employ about 45,000 people. Essentia Health facilities will retain the Essentia name as operations are integrated. The transaction is expected to take effect Jan. 1, pending regulatory approvals. Fitch said it views the proposed transaction as neutral to Essentia’s rating.”
- Beckers ASC Review tells us,
- “Health systems have bought independent practices in orthopedics, family medicine, women’s health and dermatology this fall. One of the deals came out of a bankruptcy auction, and another is being challenged in court.
- “[The article discusses] five deals involving an independent practice acquired by a health system that Becker’s has reported on since Sept. 1, 2026.”
- Modern Healthcare explains “why independent physicians opt for ‘umbrella mergers’”.
- “An umbrella merger is when a group of independent physician practices combine under a single corporate entity.
- “Umbrella mergers give physicians access to more resources and create leverage in contract negotiations, while still maintaining some autonomy.
- “The model is not a quick fix for struggling practices and requires a time commitment to build a leadership structure and establish protocols.”
- Healthcare Dive informs us,
- “Physicians’ AI use is moving beyond administrative tasks to more everyday clinical decision support, like searching through medical literature, according to a survey published Thursday by Doximity.
- “More than half of physicians said they use AI daily and another third use it at least once a week, the medical professional and technology firm reported. Most physicians also said that AI has taught them clinical knowledge they didn’t already know.
- “Still, physicians remained concerned about AI eroding their skills, with more than half saying they specifically worry about how AI use will impact the development of residents, fellows or trainees they supervise.”
